Welcome to our dedicated page for I:SPX Oct 2023 Weekly 3100.000 news (Ticker: INFI), a resource for investors and traders seeking the latest updates and insights on I:SPX Oct 2023 Weekly 3100.000 stock.
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing, and delivering best-in-class medicines for the treatment of challenging diseases, with a particular focus on oncology and inflammation. The company harnesses its robust small molecule discovery and development capabilities to address unmet medical needs.
Infinity's research and development programs stem from the integration of a broad spectrum of scientific expertise, including cancer biology, medicinal chemistry, clinical and translational medicine, and drug product process development and formulation. This multidisciplinary approach enables the company to innovate and advance its pipeline of potential therapies effectively.
Strategic Alliances
Infinity Pharmaceuticals has established substantial partnerships with leading pharmaceutical and biotechnology companies. These alliances are crucial in maximizing the potential of Infinity's product pipeline, allowing the company to leverage external expertise and resources in its quest to bring new treatments to market.
Business and Scientific Expertise
The company's team is composed of passionate, committed, and innovative professionals who bring together a wealth of experience in various fields. This collective expertise is pivotal in driving the company's mission forward, from early-stage research to clinical development and commercialization.
Infinity Pharmaceuticals continuously updates its stakeholders and the public with the latest news and developments. Keeping abreast of these updates is essential for anyone interested in the company's progress and its impact on the pharmaceutical landscape.
Infinity Pharmaceuticals announces the appointment of Robert Ilaria, Jr. as Chief Medical Officer, leading the clinical development of eganelisib, an oral immuno-oncology therapeutic. Ilaria brings extensive oncology experience, notably from his roles at Bristol Myers Squibb and Celgene. Brian Schwartz, previously Consulting Chief Physician, transitions to the Board of Directors. The press release highlights the promising data from ongoing studies, particularly in treating bladder and triple negative breast cancers, with plans for future development and registration studies.
Infinity Pharmaceuticals (NASDAQ: INFI) announced participation in two upcoming virtual healthcare conferences. The Wells Fargo Virtual Healthcare Conference will feature a fireside chat on September 9, 2021, at 2:40 PM ET, with 1-on-1 meetings on September 9-10. The H.C. Wainwright 23rd Annual Global Investment Conference will present on-demand on September 13, 2021, at 7 AM ET, with 1-on-1 meetings from September 13-15. Presentations will be available on Infinity's website for 30 days.
Infinity Pharmaceuticals (Nasdaq: INFI) announced the grant of inducement stock options and restricted stock units to newly hired Chief Scientific Officer, Dr. Stephane Peluso. The stock option award includes an option to purchase 250,000 shares at an exercise price of $2.93, vesting over four years. Additionally, a restricted stock unit award for 50,000 shares will vest fully on the first anniversary of the grant. These awards are part of Dr. Peluso's compensation and align with Nasdaq regulations concerning inducements for new executives.
Infinity Pharmaceuticals (Nasdaq: INFI) has announced significant data from its Phase 2 trials MARIO-275 and MARIO-3, focusing on eganelisib, an oral immuno-oncology treatment. In MARIO-275, the combination of eganelisib and nivolumab showed a median overall survival (mOS) of 15.4 months in advanced urothelial cancer, compared to 7.9 months for the control. MARIO-3 demonstrated an 86.8% disease control rate in patients with advanced triple-negative breast cancer. The company plans to work with regulatory bodies to strategize clinical paths forward and provide updates before year-end.
Infinity Pharmaceuticals reported its second quarter 2021 results, highlighting progress with eganelisib, an oral immuno-oncology therapy. Promising data indicated eganelisib enhances survival rates in metastatic urothelial cancer and progression-free survival in triple-negative breast cancer (TNBC) when combined with standard treatments. Financially, the company recorded a net loss of $11.3 million, or $0.13 per share. By year-end, Infinity anticipates cash reserves between $70 million and $80 million. Dr. Stéphane Peluso was appointed Chief Scientific Officer, reinforcing the R&D team.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) is hosting a key opinion leader webinar on July 27, 2021, at 8 am Eastern Time, to discuss updates on its clinical studies, MARIO-3 and MARIO-275, involving the drug eganelisib.
MARIO-3 evaluates eganelisib in combination with Tecentriq and Abraxane for front-line triple-negative breast cancer (TNBC), while MARIO-275 studies its addition to Opdivo for second-line urothelial cancer (UC). Presentations will include updated data, with expert insights from Dr. Erika P. Hamilton and Dr. Brian Schwartz.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced that Dr. Brian Schwartz will present eganelisib's clinical data at the Keystone Symposia on June 21, 2021. The presentation titled "Eganelisib Activity as a Macrophage Reprogramming Therapeutic Candidate" will cover results from studies involving metastatic TNBC and urothelial cancer. The session will include a Q&A segment. The webcast will be available on Infinity's website for 30 days post-event. Eganelisib represents an innovative approach to combat immune suppression in cancer.
Infinity Pharmaceuticals (NASDAQ: INFI) reported its Q1 2021 financial results, highlighting the ongoing development of eganelisib, an oral immuno-oncology therapy. The company's cash reserves grew significantly to $106.8 million from $34.1 million at the end of 2020, bolstered by a $92 million public offering. Infinity anticipates a net loss between $40 million to $50 million for 2021. Upcoming data presentations from the MARIO-3 and MARIO-275 studies are expected on July 27, potentially shaping future registration studies in breast and bladder cancer indications.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology firm, will hold a conference call on May 13, 2021, at 4:30 PM ET to discuss its Q1 2021 financial results. The call will cover updates on eganelisib, an immuno-oncology drug under development aimed at reprogramming macrophages to combat immune suppression in cancer. Notable studies include MARIO-275 and MARIO-3, focusing on various combinations of eganelisib with other cancer therapies. A live webcast will be available on their website.
Infinity Pharmaceuticals (NASDAQ: INFI) announces a presentation summarizing recent clinical data on eganelisib, a potential first-in-class oral immuno-oncology therapy. The event will occur during the New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2021 virtual symposium from May 12-14, 2021. The presentation titled 'Eganelisib Activity as a Macrophage Reprogramming Therapeutic' will be held on May 12 at 1:26 pm ET. Attendees can access the presentation on Infinity's website, available for 30 days post-event.
FAQ
What is the market cap of I:SPX Oct 2023 Weekly 3100.000 (INFI)?
What is the primary focus of Infinity Pharmaceuticals?
What capabilities does Infinity Pharmaceuticals possess?
Who are Infinity Pharmaceuticals' strategic partners?
What is the mission of Infinity Pharmaceuticals?
What makes Infinity Pharmaceuticals unique?
What areas of expertise does the Infinity team bring together?
How does Infinity Pharmaceuticals contribute to the pharmaceutical field?
Where can I get the latest updates about Infinity Pharmaceuticals?
What types of diseases is Infinity Pharmaceuticals targeting?
Why are strategic alliances important for Infinity Pharmaceuticals?
